IP Library Granted Patent US 10,322,077
Granted Patent B2
US 10,322,077 · App. 15/008,699 · Granted Jun 18, 2019

Methods and compositions for tattoo removal

Inventors: Stephen G. Carter (Andover, MA); Zhen Zhu (Andover, MA); Kanu Patel (Londonderry, NH); Diane L. Kozwich (Nottingham, NH); Laura Stephens (Danvers, MA); John J. Masiz (Topsfield, MA); David H. Donabedian (Providence, RI)
Assignee: BioChemics, Inc.
A61K8/4926A61B18/203A61K8/0208A61K8/26A61K8/342A61K8/498A61K8/585A61K8/678A61K8/73A61K8/922A61Q1/145A61Q19/02A61B2017/00769A61B2018/0047A61B2018/00452A61K2800/51A61K2800/74A61K2800/81A61K2800/91A61M37/0092A61N1/325A61N5/062
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,322,077
App. No.
15/008,699
Granted
Jun 18, 2019
Kind
B2
Abstract

Methods and formulations for removing a tattoo by using a cell disrupter in combination with a vasodilator, and optionally one or more of an osmotic modifying agent, a chelation agent, and an occlusive modifying agent. Embodiments optionally further include using one or more of an antibiotic, anesthetic, penetration enhancer, excipient, carrier and vehicle.

Claims (23)

1. A method of removing a tattoo from a region of skin, the method comprising

treating the region with a cell disruptor so as to cause cells of the skin to rupture; and

administering to the same region a tattoo removal composition comprising

a vasodilator,

at least one osmotic modifying agent in an amount sufficient to draw water from cells and vasculature of the skin,

and at least one chelating agent,

so as to cause enlargement of blood vessels in the region, so that the action of the composition and the cell disruptor causes removal of the tattoo.

2. The method of claim 1 , wherein administering the composition includes applying the composition topically to the region.

3. The method of claim 1 , wherein administering the composition includes applying the composition via a transdermal patch.

4. The method of claim 1 , wherein administering the composition includes injecting the composition into the region of skin with a suitable medical device.

5. The method of claim 4 , wherein injecting the composition includes using any one of a hypodermic needle, a syringe, and a needleless injection device.

6. The method of claim 1 , wherein administering the composition includes delivering the composition by one or more of a topical formulation, a patch-like device, an iontophoresis device, a sonophoresis device, and an injection.

7. The method of claim 1 , wherein administering the composition includes covering the region with a non-breathable occlusive barrier that dries on the skin.

8. The method of claim 1 , wherein administering the composition includes covering the region with a physical non-breathable occlusive barrier.

9. The method of claim 1 , wherein treating the region with the cell disruptor includes using externally applied energy.

10. The method of claim 9 , wherein treating the region with the cell disruptor includes using a laser.

11. The method of claim 9 , wherein treating the region with the cell disruptor includes using externally applied energy derived from at least one of thermal, sonic, ultrasound, visible light, infrared light, ultraviolet light, electric, magnetic, chemical, enzymatic, mechanical, and any other type of energy.

12. The method of claim 1 , wherein treating the region with the cell disruptor takes place after administering the composition.

13. The method of claim 1 , wherein treating the region with the cell disruptor takes place before administering the composition.

14. The method of claim 1 , wherein treating the region with the cell disruptor takes place coincident with administering the composition.

15. The method of claim 1 , wherein administering the composition occurs in a single dose.

16. The method of claim 1 , wherein administering the composition occurs in one of multiple doses and multiple times per day.

17. The method of claim 1 , wherein administering the composition includes administering it to one of a human and a non-human animal.

Assignments (3)
BILL OF SALE AND COURT ORDER Recorded Apr 14, 2021
From: BIOCHEMICS, INC.
To: CONVERGENT DISTRIBUTORS OF TEXAS LLC
Reel/Frame 055927/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2016
From: CARTER, STEPHEN G.; ZHU, ZHEN; PATEL, KANU; KOZWICH, DIANE L.; STEPHENS, LAURA; MASIZ, JOHN J.; DONABEDIAN, DAVID H.
To: BIOCHEMICS, INC.
Reel/Frame 039640/0770 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2016
From: CARTER, STEPHEN G.; ZHU, ZHEN; PATEL, KANU; KOZWICH, DIANE L.; STEPHENS, LAURA; MASIZ, JOHN J.; DONABEDIAN, DAVID H.
To: BIOCHEMICS, INC.
Reel/Frame 038251/0903 →
Continuity (3)
Continuation 12631698 · Dec 4, 2009
Provisional Application 61120009 · Dec 4, 2008
Related Publication 20160213586A1 · Jul 28, 2016
Cited By (2)
US 12,246,098 US 12,605,345